A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Trial Profile

A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2018

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 30 Jul 2018 Planned initiation date changed from 31 May 2020 to 10 May 2020.
    • 12 Jun 2018 Planned End Date changed from 12 Apr 2020 to 24 May 2022.
    • 12 Jun 2018 Planned primary completion date changed from 25 Feb 2019 to 13 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top